Yaser Souri, Edgar Franklin Hernandez Cancino, Hagen Kerndl, Alexander Hyhlik-Duerr, Yvonne Gosslau
{"title":"PowerGlide Pro 中线导管的临床评估--包括前列腺素在内的各种药物的停留时间、并发症和疗效。","authors":"Yaser Souri, Edgar Franklin Hernandez Cancino, Hagen Kerndl, Alexander Hyhlik-Duerr, Yvonne Gosslau","doi":"10.1007/s00423-024-03546-y","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>The PowerGlide Pro™ Midline Catheter is a peripheral venous access device with a length of 8-10 cm, allowing the tip to reach far into the venous system. The aim of this study was to evaluate the dwell time of the catheter. Secondary endpoints included suitability for specific medications (e.g. prostaglandins) and assessment of complications.</p><p><strong>Methods: </strong>Between January 2019 and November 2021, 50 patients were included in the study. Data on patient demographics, placement characteristics, complications and reasons for removal, were collected.</p><p><strong>Results: </strong>Placement was technically successful in 92% (n = 46) of cases. In all cases, veins of the upper extremity were punctured (34 basilic veins, 7 brachial veins, 6 cephalic veins, and 3 median cubital veins). The average dwell time was 6.1 days (1-17 days). A significant difference between duration and medication administered could not be demonstrated.</p><p><strong>Conclusions: </strong>The longer maximum dwell time compared to a standard peripheral venous catheter makes it particularly suitable for intravenous therapy for more than 7 days or patients who have poor peripheral vein status.</p>","PeriodicalId":17983,"journal":{"name":"Langenbeck's Archives of Surgery","volume":"409 1","pages":"363"},"PeriodicalIF":2.1000,"publicationDate":"2024-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11602871/pdf/","citationCount":"0","resultStr":"{\"title\":\"Clinical evaluation of the PowerGlide Pro midline catheter- dwell time, complications and outcomes for various medications including prostaglandins.\",\"authors\":\"Yaser Souri, Edgar Franklin Hernandez Cancino, Hagen Kerndl, Alexander Hyhlik-Duerr, Yvonne Gosslau\",\"doi\":\"10.1007/s00423-024-03546-y\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>The PowerGlide Pro™ Midline Catheter is a peripheral venous access device with a length of 8-10 cm, allowing the tip to reach far into the venous system. The aim of this study was to evaluate the dwell time of the catheter. Secondary endpoints included suitability for specific medications (e.g. prostaglandins) and assessment of complications.</p><p><strong>Methods: </strong>Between January 2019 and November 2021, 50 patients were included in the study. Data on patient demographics, placement characteristics, complications and reasons for removal, were collected.</p><p><strong>Results: </strong>Placement was technically successful in 92% (n = 46) of cases. In all cases, veins of the upper extremity were punctured (34 basilic veins, 7 brachial veins, 6 cephalic veins, and 3 median cubital veins). The average dwell time was 6.1 days (1-17 days). A significant difference between duration and medication administered could not be demonstrated.</p><p><strong>Conclusions: </strong>The longer maximum dwell time compared to a standard peripheral venous catheter makes it particularly suitable for intravenous therapy for more than 7 days or patients who have poor peripheral vein status.</p>\",\"PeriodicalId\":17983,\"journal\":{\"name\":\"Langenbeck's Archives of Surgery\",\"volume\":\"409 1\",\"pages\":\"363\"},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2024-11-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11602871/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Langenbeck's Archives of Surgery\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s00423-024-03546-y\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"SURGERY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Langenbeck's Archives of Surgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00423-024-03546-y","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"SURGERY","Score":null,"Total":0}
Clinical evaluation of the PowerGlide Pro midline catheter- dwell time, complications and outcomes for various medications including prostaglandins.
Purpose: The PowerGlide Pro™ Midline Catheter is a peripheral venous access device with a length of 8-10 cm, allowing the tip to reach far into the venous system. The aim of this study was to evaluate the dwell time of the catheter. Secondary endpoints included suitability for specific medications (e.g. prostaglandins) and assessment of complications.
Methods: Between January 2019 and November 2021, 50 patients were included in the study. Data on patient demographics, placement characteristics, complications and reasons for removal, were collected.
Results: Placement was technically successful in 92% (n = 46) of cases. In all cases, veins of the upper extremity were punctured (34 basilic veins, 7 brachial veins, 6 cephalic veins, and 3 median cubital veins). The average dwell time was 6.1 days (1-17 days). A significant difference between duration and medication administered could not be demonstrated.
Conclusions: The longer maximum dwell time compared to a standard peripheral venous catheter makes it particularly suitable for intravenous therapy for more than 7 days or patients who have poor peripheral vein status.
期刊介绍:
Langenbeck''s Archives of Surgery aims to publish the best results in the field of clinical surgery and basic surgical research. The main focus is on providing the highest level of clinical research and clinically relevant basic research. The journal, published exclusively in English, will provide an international discussion forum for the controlled results of clinical surgery. The majority of published contributions will be original articles reporting on clinical data from general and visceral surgery, while endocrine surgery will also be covered. Papers on basic surgical principles from the fields of traumatology, vascular and thoracic surgery are also welcome. Evidence-based medicine is an important criterion for the acceptance of papers.